Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001858529 | SCV002232937 | pathogenic | Charcot-Marie-Tooth disease type 2 | 2021-03-22 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Phe240 ‚Äãamino acid residue in MFN2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 26382835, Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MFN2 protein function. A different variant (c.720C>A) giving rise to the same protein effect has been determined to be pathogenic (Invitae). This suggests that this variant is also likely to be causative of disease. ClinVar contains an entry for this variant (Variation ID: 694947). This variant is not present in population databases (ExAC no frequency). This sequence change replaces phenylalanine with leucine at codon 240 of the MFN2 protein (p.Phe240Leu). The phenylalanine residue is highly conserved and there is a small physicochemical difference between phenylalanine and leucine. |
| Genesis Genome Database | RCV000857098 | SCV000999671 | uncertain significance | Charcot-Marie-Tooth disease | 2019-08-14 | no assertion criteria provided | research |